SCYNEXIS Announces Pricing of $22.5 Million Public Offering of Common Stock and Warrants Jun 21, 2016
SCYNEXIS Inc. Presents New Clinical and Non-Clinical Data Confirming the Potential of SCY-078 as a Novel Treatment for Life-threatening Fungal Infections Jun 20, 2016
SCYNEXIS to Present Data from Lead Antifungal Drug Candidate SCY-078 at ASM Microbe 2016 Jun 10, 2016
SCYNEXIS, Inc. Announces Positive Results in its Proof-of-Concept Phase 2 Study of SCY-078, the First Member of a Novel Class of Glucan Synthase Inhibitors Jun 8, 2016
SCYNEXIS, Inc. Receives Orphan Drug Designation for SCY-078 for the Treatment of Invasive Candida Infections May 13, 2016
SCYNEXIS Receives Designation as a Small and Medium Enterprise by the European Medicines Agency Apr 19, 2016
SCYNEXIS Presents Data Supporting the Activity of its Lead Antifungal Drug Candidate SCY-078 Against Antifungal-resistant Candida Strains at the 13th ASM Conference on Candida and Candidiasis Apr 15, 2016
